Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab + ISA101b in recurrent/metastatic HPV16 cervical cancer after first-line chemotherapy
2020-001239-29Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and SLP-HPV-01 in Cervical Cancer (CC), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Objective response rate. Started Feb 2021; status: completed.
02
Drugs
cemiplimabSLP-HPV-01
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2020-001239-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001239-29.